Physicians recommend that patients with chronic obstructive pulmonary disease (COPD) quit smoking and use steroids, ...
High unmet medical need for therapies that can reduce the substantial treatment burden affecting millions of patients globallyCombined in-licensing and ...
For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.
Key Takeaways Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for ...
Boobalan Pachaiyappan, an analyst from Roth MKM, has initiated a new Buy rating on Verona Pharma (VRNA).Stay Ahead of the Market:Discover ...
1d
Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...
The Texas Tech University Health Sciences Center is offering a new treatment for patients suffering from severe chronic ...
Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.
But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.
A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback